论文部分内容阅读
目的检测乳腺癌患者血浆TSP-1及VEGF在化疗前后的变化,探讨其临床意义。方法应用酶联免疫吸附法(ELISA)对40例乳腺癌患者化疗前后血浆TSP-1及VEGF测定并对照分析。结果乳腺癌患者化疗前血浆TSP-1为95.56±40.66)ng/ml,VEGF为566.2±46.8ng/ml;化疗2个周期后TSP-1为167.14±56.78)ng/ml,VEGF为465.2±200.6ng/ml,P<0.01。结论乳腺癌患者化疗前后血浆TSP-1及VEGF水平的变化与化疗效果密切相关,TSP-1及VEGF可作为判断化疗疗效的指标之一。
Objective To detect the changes of plasma TSP-1 and VEGF in patients with breast cancer before and after chemotherapy, and to explore its clinical significance. Methods The levels of plasma TSP-1 and VEGF in 40 patients with breast cancer before and after chemotherapy were measured and compared by enzyme-linked immunosorbent assay (ELISA). Results The TSP-1 level in patients with breast cancer before chemotherapy was 95.56 ± 40.66 ng / ml, VEGF was 566.2 ± 46.8 ng / ml, TSP-1 was 167.14 ± 56.78 ng / ml after 2 cycles of chemotherapy, and VEGF was 465.2 ± 200.6 ng / ml, P <0.01. Conclusion The changes of plasma TSP-1 and VEGF levels in patients with breast cancer before and after chemotherapy are closely related to the effect of chemotherapy. TSP-1 and VEGF may be used as indicators to evaluate the efficacy of chemotherapy.